Induction of heme oxygenase-1 and heat shock protein 70 in rat hepatocytes: The role of calcium signaling

Silomon, M.; Bauer, Inge; Bauer, Michael; Nolting, Julia; Paxian, Markus; Rensing, Hauke

doi:10.2478/s11658-006-0052-0

Cited by 7 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Txnrd1, which (together with Hmox1) is a part of the anti-oxidation system, was not upregulated in any muscles of SJL mice. Recently, Ca-dependent upregulation of Hsp70 and Hmox-1 in skeletal muscle cells and in hepatocytes has been reported 63 , 64 . Because DYSF-null muscle fibers are defective in Ca 2+ -dependent resealing of disruptions of the sarcolemma 19 , these muscle fibers may cause persistent influx of Ca into the cytoplasm after membrane injury.…”

Section: Animal Models For Dysferlinopathymentioning

confidence: 99%

Dysferlin and Animal Models for Dysferlinopathy

et al. 2012

View full text Add to dashboard Cite

Dysferlin (DYSF) is involved in the membrane-repair process, in the intracellular vesicle system and in T-tubule development in skeletal muscle. It interacts with mitsugumin 53, annexins, caveolin-3, AHNAK, affixin, S100A10, calpain-3, tubulin and dihydropyridine receptor. Limb-girdle muscular dystrophy 2B (LGMD2B) and Miyoshi myopathy (MM) are muscular dystrophies associated with recessively inherited mutations in the DYSF gene. The diseases are characterized by weakness and muscle atrophy that progress slowly and symmetrically in the proximal muscles of the limb girdles. LGMD2B and MM, which are collectively termed “dysferlinopathy”, both lead to abnormalities in vesicle traffic and membrane repair at the plasma membrane in muscle fibers. SJL/J (SJL) and A/J mice are naturally occurring animal models for dysferlinopathy. Since there has been no an approach to therapy for dysferlinopathy, the immediate development of a therapeutic method for this genetic disorder is desirable. The murine models are useful in verification experiments for new therapies and they are valuable tools for identifying factors that accelerate dystrophic changes in skeletal muscle. It could be possible that the genetic or immunological background in SJL or A/J mice could modify muscle damage in experiments involving these models, because SJL and A/J mice show differences in the progress and prevalent sites of skeletal muscle lesions as well as in the gene-expression profiles of their skeletal muscle. In this review, we provide up-to-date information on the function of dysferlin, the development of possible therapies for muscle dystrophies (including dysferlinopathy) and the detection of new therapeutic targets for dysferlinopathy by means of experiments using animal models for dysferlinopathy.

show abstract

Section: Animal Models For Dysferlinopathymentioning

confidence: 99%